{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-021627","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.034490+00:00","generated_at":"2026-05-14T21:24:57.785972+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"confidence":"high","headline":"Oragenics signs LOI to license CardioDialysis from Sigyn Therapeutics for TBI","bullets":["LOI grants Oragenics exclusive license for CardioDialysis blood purification tech in TBI and chronic neurodegenerative diseases.","Consideration: 3,250,000 shares of preferred stock convertible 1:1 to common, plus 3% royalty for 6 years post-FDA clearance.","Target closing within 90 days; Sigyn exclusivity during that period; subject to due diligence, board approvals, and NYSE American rules.","Oragenics also advancing ONP-002 (Phase IIa intranasal neurosteroid); combined approach targets TBI inflammation on both sides of BBB.","No FDA-approved pharmacological treatment for concussion/mTBI; 69 million brain injuries occur annually worldwide."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-021627","json":"https://secwatch.observer/filing/0001493152-26-021627.json","markdown":"https://secwatch.observer/filing/0001493152-26-021627.md","text":"https://secwatch.observer/filing/0001493152-26-021627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315226021627/0001493152-26-021627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315226021627/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:24:57.785972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}